Epigenomics AG
Epigenomics AG does not have significant operations. Previously, the company was involved in liquid biopsy for the early detection of cancer. The company was founded in 1998 and is headquartered in Heidelberg, Germany.
Epigenomics AG (EPGNF) - Total Assets
Latest total assets as of June 2025: $11.86 Million USD
Based on the latest financial reports, Epigenomics AG (EPGNF) holds total assets worth $11.86 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Epigenomics AG - Total Assets Trend (2003–2024)
This chart illustrates how Epigenomics AG’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Epigenomics AG - Asset Composition Analysis
Current Asset Composition (December 2024)
Epigenomics AG's total assets of $11.86 Million consist of 98.1% current assets and 1.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 93.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how Epigenomics AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Epigenomics AG's current assets represent 98.1% of total assets in 2024, an increase from 73.1% in 2003.
- Cash Position: Cash and equivalents constituted 93.6% of total assets in 2024, up from 58.8% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 26.0% in 2003.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Epigenomics AG Competitors by Total Assets
Key competitors of Epigenomics AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Epigenomics AG - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Epigenomics AG generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Epigenomics AG is currently not profitable relative to its asset base.
Epigenomics AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 22.19 | 1.93 | 3.04 |
| Quick Ratio | 22.19 | 1.84 | 2.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $763.00K | $ 2.01 Million | $ 6.34 Million |
Epigenomics AG - Advanced Valuation Insights
This section examines the relationship between Epigenomics AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.45 |
| Latest Market Cap to Assets Ratio | 0.48 |
| Asset Growth Rate (YoY) | -92.0% |
| Total Assets | $1.02 Million |
| Market Capitalization | $491.44K USD |
Valuation Analysis
Below Book Valuation: The market values Epigenomics AG's assets below their book value (0.48 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Epigenomics AG's assets decreased by 92.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Epigenomics AG (2003–2024)
The table below shows the annual total assets of Epigenomics AG from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.02 Million | -92.02% |
| 2023-12-31 | $12.84 Million | -18.97% |
| 2022-12-31 | $15.85 Million | -35.73% |
| 2021-12-31 | $24.66 Million | +262.85% |
| 2020-12-31 | $6.80 Million | -51.41% |
| 2019-12-31 | $13.99 Million | -35.91% |
| 2018-12-31 | $21.83 Million | +10.39% |
| 2017-12-31 | $19.77 Million | +8.51% |
| 2016-12-31 | $18.22 Million | +44.64% |
| 2015-12-31 | $12.60 Million | +11.29% |
| 2014-12-31 | $11.32 Million | +2.16% |
| 2013-12-31 | $11.08 Million | +61.11% |
| 2012-12-31 | $6.88 Million | -64.66% |
| 2011-12-31 | $19.46 Million | -42.48% |
| 2010-12-31 | $33.84 Million | +106.91% |
| 2009-12-31 | $16.35 Million | -19.37% |
| 2008-12-31 | $20.28 Million | -11.48% |
| 2007-12-31 | $22.91 Million | -23.96% |
| 2006-12-31 | $30.13 Million | -33.03% |
| 2005-12-31 | $45.00 Million | -15.55% |
| 2004-12-31 | $53.28 Million | +70.20% |
| 2003-12-31 | $31.31 Million | -- |